RVPH | tickerfilter.com

Fundamental analysis

38%

Profitability 35%

Dept financing 43%

Liquidity 42%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

1,361.37%

1 Month

890.14%

3 Months

284.45%

6 Months

489.03%

1 Year

125.00%

2 Year

-21.39%

Key data

Stock price

$2.61

P/E Ratio

0.00

DAY RANGE

$2.57 - $3.11

EPS

-$0.57

52 WEEK RANGE

$0.17 - $3.52

52 WEEK CHANGE

$126.96

MARKET CAP

25.066 M

YIELD

N/A

SHARES OUTSTANDING

115.059 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-13-2025

BETA

0.12

PUBLIC FLOAT

AVERAGE 10 VOLUME

$3,153,499

AVERAGE 30 VOLUME

$3,115,799

Company detail

CEO: Laxminarayan Bhat
Region: US
Website: revivapharma.com
Employees: 5
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia. RP1208 that is in pre-clinical development studies for depression and obesity.

RVPH - REVIVA PHARMACEUTICALS HOLDINGS, INC.